However, in vivo testing in the Col1a2+/p.G610C mouse demonstrated that while some OI bone trabecular properties were improved, off‐target effects suppressing longitudinal and transverse bone growth in OI mice precluded rapamycin as a viable therapeutic option.9 Here, COL1A2 is linked to osteogenesis imperfecta.